Decentralized clinical trials (DCTs) have become a buzzphrase in recent years, with commentators lining up to extol the benefits of this new way of working. Practical advice on how to adopt and implement the model, however, has been thinner on the ground. Organizations may still be wary of their return on investment (ROI) when it comes to implementing these developing practices.
That’s why CluePoints was delighted to be invited to participate in a DCT case study session at the upcoming Society for Clinical Data Management (SCDM) EMEA Leadership Forum and Conference.
SCDM 2022 EMEA marks the return of face-to-face conferences for the organization, which is the world’s leading advocate for the discipline of clinical data management. The event will be held in Basel, Switzerland, from June 22nd to 24th, focusing on the innovations and changes affecting the sector in Europe, the Middle East, and Africa.
From Site-Based Trials to Virtual and Decentralized Clinical Trials
Chief among the industry shifts under the spotlight will be the move from site-based to virtual and decentralized clinical trials that’s accelerated since the advent of COVID-19.
The model, which expands access to clinical trials and reduces participant burden, has many benefits. For example, it can boost retention and recruitment rates, and help build more inclusive and diverse study cohorts. By enabling researchers to replace site-based source data verification (SDV) with centralized monitoring, DCTs can contribute to conducting safer, more efficient studies.
How can we support the successful collection of robust, reliable data in this new model? What is the measured cost of getting something wrong? What are the primary considerations, complexities, and common pitfalls?
The Future and ROI of Virtual and Decentralized Clinical Trials
The SCDM 2022 EMEA session Disruptive Technologies Simplified: Real-World Case Studies being held on Thursday, June 23rd from 3:45 to 5:00 pm will answer all these questions.
Technology and industry leaders will share their own stories about the positives and negatives they’ve encountered over the last few years while implementing models such as risk-based quality management (RBQM), artificial intelligence (AI), machine learning (ML), and robotic process automation (RPA).
Adriaan Kruger, Co-Founder and CEO of nuvoteQ.io, will chair the session. He’ll be joined by David Anderson, Senior Scientist at Clinical Ink, Colin Pillai, CEO of CP+ Associates GmbH, and Cluepoints’ VP Solution Expert, Rich Davies. Between this group, they’ll provide practical advice, hints, and tips on embracing the potential of DCTs, highlighting the risks sponsors and CROs need to be aware of.
For more information on the session, or to register for SCDM 2022 EMEA Leadership Forum & Conference, click here.
